Search research articles
Contact Us
Filters
Showing results (221-230 of 227) with videos related to
Page
of 23
Sort By:
You have reached the last page of results.
This site can display upto 227 results.
Breast (Edinburgh, Scotland)
|
October 8, 2013
Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial
F Valet, P de Cremoux, F Spyratos, et al.
British Journal of Cancer
|
May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
C Le Tourneau, B Dreno, Y Kirova, et al.
ESMO Open
|
May 16, 2025
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO)
A-S Hamy, B Grandal, F Jochum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
S Delaloge, D Pérol, C Courtinard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Page
of 23
Search research articles
Search
Showing results (221-230 of 227) with videos related to
Sort By:
Page
of 23
You have reached the last page of results.
This site can display upto 227 results.
Breast (Edinburgh, Scotland)
|
October 8, 2013
Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial
F Valet, P de Cremoux, F Spyratos, et al.
British Journal of Cancer
|
May 4, 2016
First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma
C Le Tourneau, B Dreno, Y Kirova, et al.
ESMO Open
|
May 16, 2025
Causal analyses of the impact of comorbid conditions and concomitant medications on response to neoadjuvant chemotherapy in breast cancer: analysis of a multicenter prospective cohort study (CANTO)
A-S Hamy, B Grandal, F Jochum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
S Delaloge, D Pérol, C Courtinard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Page
of 23